IGCAN Directory
login/create account
DonateHome > About > News
Latest Story
Recent Stories
Renew or Join
Its membership renewal season and the perfect time to join IGCS if you are not currently a member. All dues payments are applied to the 2026 membership term. IGCS provides year-round education, mentorship and training opportunities, and most recently, advocacy and outreach programming in support of our mission.
PRIME Researchship
The PRIME Fellowship is a 2-year, virtual postdoctoral research program led by Drs. Alexander Melamed and J. Alejandro Rauh-Hain. Designed to build global research capacity in gynecologic oncology, this fellowship offers advanced mentorship in innovative statistical methods, hands-on work with real-world oncology datasets, and the opportunity to produce high-impact research alongside leading investigators. Now accepting applications, deadline is January 30, 2026.
Landmark Global Study on Ovarian Cancer Published in The Lancet Obstetrics, Gynaecology & Women’s Health
We are pleased to share important news for our global community. A major new international study, “Experiences of Women with Ovarian Cancer in 22 Low- and Middle- Income Countries (Every Woman Study™ LMIC): a Cross-sectional Study,” was published today in the The Lancet Obstetrics, Gynaecology, & Women’s Health.
Upcoming Events
List of events in Photo View
-
Jan 30 - Jan 31
Una Mirada Completa Al Cancer En La Mujer
-
Feb 5 - Feb 6
The Bristol Gynaecology Oncology course
-
Mar 27 - Mar 28
12th International Symposium on Gynecologic Oncology
More Stories
I am pleased to announce an incredible addition to the IGCS team, Ms. Mary (Dicey) Jackson Scroggins who will lead IGCS’s patient advocacy and community outreach efforts as the Society’s first Director of Global Outreach and Engagement. Dicey is a 22-year ovarian cancer survivor and women’s health activist with extensive relationships throughout cancer advocacy and research communities.
The IGCS Council recently discussed and approved the concept of IGCS centering its advocacy efforts around the theme “empowerment”. Empowering women, caregivers and others interested in making a difference with tools and resources to increase their level of autonomy and enable them to represent the specific needs within their region. This may include screening and vaccination, funding and support for clinical trials, research, and access to better care.
It is with great excitement that I announce the Middle East and Mediterranean Association of Gynecologic Oncologists (MEMAGO) as our latest organization to join the IGCS Strategic Alliance Partner Program. In the Mediterranean and Middle East, some of the major goals are to standardize patient management and to spread these standards to all areas in the region. Due to this new partnership between MEMAGO and IGCS, the societies will work together to offer more opportunities for training and help bring new techniques and technologies to areas of the region.
It is our pleasure to announce that the International Society of Gynecological Pathologists (ISGyP) has joined the IGCS Strategic Alliance Partner Program bringing over 350 new members to the IGCS. Pathology is the cornerstone of the care of our patients and IGCS looks forward to working with ISGyP to increase the collaboration between pathologists and multidisciplinary cancer teams. By working together, we have the potential to make great advances in improving outcomes for women affected by gynecological cancer.
I am very pleased to announce a new member in the Strategic Alliance Partner Program, the Society of Gynecologic Oncologists of the Philippines (SGOP). SGOP is an exemplary organization of gynecologic oncologists and specialists of related disciplines committed to the continuous upgrading of the standards of practice, teaching and research in the field of gynecologic oncology in the Philippines. Much like IGCS, the members of the Society of Gynecologic Oncologists of the Philippines agree that a high standard of practice in gynecologic oncology is essential for all women diagnosed with gynecologic malignancies.